46
Overview and medical management of PPH Dr. Suhas Otiv Consultant, KEM Hospital, Pune

Overview and medical management of pph

Embed Size (px)

DESCRIPTION

By Dr. Suhas Otiv

Citation preview

Page 1: Overview and medical management of pph

Overview and medical management of PPH

Dr. Suhas OtivConsultant, KEM Hospital, Pune

Page 2: Overview and medical management of pph
Page 3: Overview and medical management of pph

Lancet 2006; l368:1189-200

Page 4: Overview and medical management of pph

Mortality from PPH

• Half of 500,000 maternal deaths globally

• 28 % of maternal deaths in developing countries

• Risk of death from PPH 1 in 1000 deliveries - developing countries1 in 100,000 deliveries – developed countries

Page 5: Overview and medical management of pph

Lancet 2006; l367:1066-72

Page 6: Overview and medical management of pph

Incidence of PPH

PPH 5 – 17 % of all deliveries> 500ml

Major PPH 1.3 – 2.5 % of all deliveries> 1000 ml

ACOG 3.9 % of all deliveries

Page 7: Overview and medical management of pph

Definition of PPH

Primary PPH: 0 – 24 hours; Secondary PPH: 1 - 84 days

Blood loss > 500 ml at vaginal delivery> 750 - 1000 ml at Cesarean

Severe PPH > 1000 ml loss at vaginal delivery

ACOG: - Fall in hematocrit 10% - Need for PRBC transfusion

Rate of blood loss: > 150ml/min or sudden loss > 1.5 – 2 l

Page 8: Overview and medical management of pph

PPH can occur with minimal vaginal bleeding !!!!

Page 9: Overview and medical management of pph

Accuracy of visual estimation of blood loss

Page 10: Overview and medical management of pph

Blood collection method

Modified –WHO

Page 11: Overview and medical management of pph

Modified –WHO

Weighing Blood loss

Page 12: Overview and medical management of pph

Modified –WHO

Measuring volume of blood loss

-Transfer of blood-Mops squeezed

Page 13: Overview and medical management of pph

BRASSS-V®

Blood Collection Drape with Calibrated Receptacle

Page 14: Overview and medical management of pph
Page 15: Overview and medical management of pph

Etiology of PPH• Uterine Atony > 80 %

• Lacerations of vagina, cervix • Uterine rupture 10%• Uterine inversion

• Retained placental fragments• Placental accreta / increta / percreta 5%

• Coagulopathy 1%

Page 16: Overview and medical management of pph

Risk factors for PPH

• Nulliparity• Obesity• Large baby• Prolonged labor• APH• Multiple pregnancy• Cesarean delivery

• Advanced maternal age• PIH• PPH in previous delivery• Augmented labor• Forceps delivery• Use of tocolyticsх Grand multiparity

65 % cases of PPH occur with no risk factors

Page 17: Overview and medical management of pph

PPH at Cesarean delivery: Risk Factors

• General anesthesia• Chorio-Amnionitis• Pre-eclampsia• Protracted active phase of labor• Second-stage arrest• Classic uterine incision

Obstet Gynecol 1991 Jan;77(1):77-82

Page 18: Overview and medical management of pph

Risk factors for PPH: a case control studycomparing 666 cases with controls in 154311 deliveries• Retained placenta (OR 3.5, 95% CI 2.1-5.8)

• Failure to progress during the second stage of labor (OR 3.4, 95% CI 2.4-4.7)

• Placenta accreta (OR 3.3, 95% CI 1.7-6.4)

• Lacerations (OR 2.4, 95% CI 2.0-2.8)

• Instrumental delivery (OR 2.3, 95% CI 1.6-3.4)

• Large for gestational age new born (eg, >4000 g) (OR 1.9, 95% CI 1.6-2.4)

• Hypertensive disorders (OR 1.7, 95% CI 1.2-2.1)

• Induction of labor (OR 1.4, 95% CI 1.1-1.7)

• Augmentation of labor with oxytocin (OR 1.4, 95% CI 1.2-1.7)

J Matern Fetal Neonatal Med. 2005;18(3):149

Page 19: Overview and medical management of pph

Management of PPH

• Scenarios – labor room, OR, wards, peripheral hospital

• Effective management– Prompt response– Organized team work – Clear priorities, decisive

• Help: communication, monitoring, assistance, documentation

Page 20: Overview and medical management of pph

Being prepared for PPH

• Team: Nursing, doctors, surgical expertise, critical care physician / anesthesiologist

• Drugs: Oxytocin, Methergin, Carboprost, volume expanders, resuscitation

• Equipment: Monitoring, resuscitation, Blood bank, Lab, ICU, OR

Page 21: Overview and medical management of pph

Management of PPH at vaginal delivery

First line Management• Call for help• Uterine massage• IV access: X-match, labs• Infuse NS rapidly, • BP, Foley catheter, pulse oximeter, • Prompt Uterotonic drugs

Carboprost 250 mcg, 2 doses 15 minutes apart Oxytocin infusion 40 units / 500 ml in 30 – 60 min Methylergometrine 0.2mg i.m. one dose Misoprostol 400 - 800mcg

• Rapidly evaluate for vaginal / cervical lacerations• Warmth, oxygen

Page 22: Overview and medical management of pph

Oxytocic drugs

• Oxytocin• Methyl ergometrine• Misoprostol• Carboprost

Page 23: Overview and medical management of pph

Oxytocin

• Storage: Between 2-8 *C, avoid freezing

• Adverse effects: anti-diuretic effect, hypotension, arrhythmias

• Incompatible with noradrenaline, warfarin

• 10 – 40 IU / L of infusate

Page 24: Overview and medical management of pph

Ergometrine

• Storage: Refrigerate, protect from light, stable for 60-90 days, discoloration – discard

• Avoid : heart disease, hypertension, peripheral vascular disease, hepatic or renal impairment; with antiretroviral and macrolide antibiotics

• Adverse : Vomiting, nausea, HT, CVA

• Route: IM preferred, IV dilute in 5 ml NS

Page 25: Overview and medical management of pph

Carboprost – PGF2 alpha

• Caution : Asthma, cardiac disease, epilepsy, liver disease

• Storage: Refrigerate• Adverse: Vomiting, diarrhea, flushing,• Dosage: 250 mcg IM, repeat every 15 - 90

minutes, maximum 8 doses = 2 mg.• IV injection - bronchospasm, hypertension,

vomiting, and anaphylaxis

Page 26: Overview and medical management of pph

Misoprostol

• PGE1 analogue• Adverse effects – vomiting, shivering at higher

doses. No broncho-constriction.• Storage: Stable at or below 25*C• Route: Oral, buccal, rectal, vaginal• Rapid onset of action lasting 4-6 h

Page 27: Overview and medical management of pph

Misoprostol as an adjunct to standard uterotonics for treatment of PPHLancet. 2010;375(9728):1808

1422 women with atonic PPH treated with routine uterotonic agents randomized to

600 mcg misoprostol sublinguallyPlacebo sublingually

Found no difference in blood loss > 500 ml in next 1 hour

Page 28: Overview and medical management of pph

Treatment of PPH with sublingual misoprostol versus oxytocin in women receiving prophylactic oxytocinLancet. 2010;375(9710):217

31055 women delivered with prophylactic oxytocin in III stage, 809 (3%) who had atonic PPH were randomized to

Misoprostol 800mcg slOxytocin 40 u infusion in 15 minutes

Similar outcomes in both groups 90% women had bleeding controlled in 20 minutes; 30% women had additional blood loss of > 300 ml after Rx

Page 29: Overview and medical management of pph

After initial treatment

• Evaluate for retained placental fragmentuterine inversionlacerationscoagulopathy

• Check urine output, response to resuscitation, timevolume of blood lost

Page 30: Overview and medical management of pph

Volume replacement

• Crystalloid: Ringer Lactate, Hartmann, NSRL similar to plasma

only 20% retained in circulationDextrose: only 10% retained, interferes with X matchingNS avoid in pre-eclamptic patient

• Blood volume changes last for 40 minutes only• Infuse 3 L for each 1 L of estimated blood loss• Target 90mm systolic pressure, UOP 30ml/hr• Give colloids after 2 L of crystalloids given

Page 31: Overview and medical management of pph

Colloids• Gelatin polymers - Hemaccel

rapid urinary excretionanaphylaxis

• Hydroxyethyl starch – Hetastarch, Pentastarchincreases plasma volume by 70 – 230%dose 20 ml/kg = 1 to 1.5 Lno anaphylactic reactions well toleratedlasts for 4 hours in circulation

Page 32: Overview and medical management of pph

Blood transfusion

• No universally accepted guidelines for trigger

• PRBC x 2 if no improvement after 2-3 L of crystalloids or if

ongoing blood loss likely

• Warm carefully. > 40 *C – severe transfusion reactions

• Admin 1 FFP for every 1-2 units of PRBC, at 12-15ml/kg

• No drugs / injections with blood

Page 33: Overview and medical management of pph

Target

• Hb > 7, • Platelets > 50,000 /ml• Fibrogen > 100mg/dl• PT < 1.5 times control

Page 34: Overview and medical management of pph

Massive hemorrhage

• Defined as > 10 units of BT required / 24 h

• Likely when persistent SBP < 90, Loss more than 1500ml

• Cryoprecipitate if no response to FFP or Fibrogen level < 100

• Expect platelet count < 50,000 after > 2 L blood loss. Platelets to maintain counts 25-50,000, 1:1

Page 35: Overview and medical management of pph

Secondary interventions

• Repeated doses of Carboprost max 8 doses• Intramyometrial Carboprost - off label• Carboprost uterine irrigation• Rectal Misoprostol - high doses >800mcg• Intra-uterine Misoprostol• Tamponade – Sengstaken tube, • Uterine Packing

Page 36: Overview and medical management of pph

Indications for laparotomy

• Unabated blood loss

• Atony unresponsive to Rx

• Vital signs out of proportion to blood loss

• Vaginal laceration extending above fornix

Page 37: Overview and medical management of pph
Page 38: Overview and medical management of pph
Page 39: Overview and medical management of pph
Page 40: Overview and medical management of pph
Page 41: Overview and medical management of pph
Page 42: Overview and medical management of pph
Page 43: Overview and medical management of pph
Page 44: Overview and medical management of pph
Page 45: Overview and medical management of pph

Summary

• Symptoms and vital signs of blood loss are more important than visual assessment of blood loss

• Team approach with protocols and regular drills

• Prompt, sequential use of utero-tonic agents and replacement of volume are mainstay of Rx

• Low Fibrinogen, abn PT, tachycardia and abnormalities of placental implantation and detectable troponin are predictors of increased morbidity

Page 46: Overview and medical management of pph

Thank you !